EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome

BioRestorative Therapies Inc BRTX has received a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health.

What Happened: The specific objective of this NIH grant is to enable the development and evaluation of the company's ThermoStem program for the treatment of polycystic ovary syndrome (PCOS).

Therapeutic brown adipocyte transplantation is an emerging and novel therapy for PCOS. The company has developed proprietary methods for generating metabolically active brown adipocytes. 

Why It Matters: "This new indication will expand BioRestorative's current discovery pipeline focused on the novel brown fat therapy at the intersection of innate, adaptive metabolic regulation and women's health," said Lance Alstodt, CEO of BioRestorative Therapies.

PCOS affects 6-18% of reproductive-age females, representing the most common endocrine disease in women and a $4.36 billion healthcare cost annually in the US. PCOS is commonly associated with metabolic disorders.

Recently, BioRestorative said license rights granted by Regenexx for intellectual property developed for chronic lumbar disc disease had been made exclusive, representing an important technological framework for its BRTX-100 lead clinical program.

Price Action: BRTX shares closed 7.33% higher at $3.66 during after-hours trading on Monday.